The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
 
Peter Hillmen
Honoraria - Abbvie; Janssen; Roche
Research Funding - Gilead Sciences (Inst); Janssen (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Abbvie; Janssen
 
Jennifer R. Brown
Honoraria - Abbvie; Janssen Oncology
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Celgene; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Pharmacyclics; Redx Pharma; Roche/Genentech; Sun Pharma
Research Funding - Gilead Sciences
 
John C. Byrd
Consulting or Advisory Role - Acerta Pharma; Genentech; Jazz Pharmaceuticals; Pharmacyclics
Research Funding - Acerta Pharma (Inst); Genentech (Inst); Janssen (Inst); Pharmacyclics (Inst)
 
Barbara Eichhorst
Honoraria - Abbvie; Celgene; Gilead Sciences; Janssen-Cilag; Novartis; Roche
Consulting or Advisory Role - Abbvie; Gilead Sciences; Janssen-Cilag; Novartis; Roche
Speakers' Bureau - Abbvie; Celgene; Gilead Sciences; Janssen-Cilag; Roche/Genentech
Research Funding - Abbvie; Gilead Sciences; Janssen; Roche
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences; Janssen; Roche
 
Nicole Lamanna
Consulting or Advisory Role - Abbvie; AstraZeneca; Celgene; Genentech; Gilead Sciences; Janssen; Juno Therapeutics; pharmacyclics; ProNAi; Roche
Research Funding - Abbvie (Inst); Acerta Pharma/AstraZeneca (Inst); AstraZeneca (Inst); Beigene (Inst); Genentech/Abbvie (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Juno Therapeutics (Inst); Loxo (Inst); ProNAi (Inst); TG Therapeutics (Inst); Verastem (Inst)
 
Susan Mary O'Brien
Employment - University of California, Irvine
Honoraria - Abbvie; Alexion Pharmaceuticals; Amgen; Aptose Biosciences; Astellas Pharma; Celgene; Eisai; Gilead Sciences; GlaxoSmithKline; Janssen; Loxo; Pfizer; Pharmacyclics; Sunesis Pharmaceuticals; TG Therapeutics; Vaniam Group
Consulting or Advisory Role - Abbvie/Genentech; Alexion Pharmaceuticals; Amgen; Aptose Biosciences; Astellas Pharma; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Pfizer; Pharmacyclics; Sunesis Pharmaceuticals; Sunesis Pharmaceuticals; TG Therapeutics; Vaniam Group
Research Funding - Acerta Pharma (Inst); Gilead Sciences (Inst); Kite, a Gilead company (Inst); Pfizer (Inst); Pharmacyclics (Inst); Regeneron (Inst); Sunesis Pharmaceuticals (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Janssen; Janssen Oncology; Regeneron
 
Lugui Qiu
No Relationships to Disclose
 
Jason C. Paik
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
James D. Hilger
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Jane Huang
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Constantine S. Tam
Honoraria - Abbvie; BeiGene; Janssen; Novartis
Research Funding - AbbVie; Janssen